| mRNA |
BEC |
CTRPv2 |
pan-cancer |
AAC |
0.28 |
0.0001 |
| mRNA |
KIN001-270 |
GDSC1000 |
pan-cancer |
AAC |
0.12 |
0.0002 |
| mRNA |
OSI-906 |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0005 |
| mRNA |
IPR-456 |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0008 |
| mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.16 |
0.0009 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.002 |
| mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.002 |
| mRNA |
JQ-1:vorinostat (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.002 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.002 |
| mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
0.003 |